| NCT01524848 |
Pazopanib in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib |
https://ClinicalTrials.gov/show/NCT01524848 |
Completed |
Scandinavian Sarcoma Group |
2015-01-31 |
| NCT03353753 |
Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies |
https://ClinicalTrials.gov/show/NCT03353753 |
Active, not recruiting |
Deciphera Pharmaceuticals LLC |
2019-05-31 |
| NCT03291054 |
Epacadostat and Pembrolizumab in Patients With GIST |
https://ClinicalTrials.gov/show/NCT03291054 |
Active, not recruiting |
Columbia University |
2021-12-31 |
| NCT03238820 |
Robotic Resection for Patients With Gastric Gastrointestinal Stromal Tumors: a Single-center Study |
https://ClinicalTrials.gov/show/NCT03238820 |
Completed |
Jinling Hospital, China |
2016-08-05 |
| NCT03171389 |
POETIG Trial - POnatinib After rEsisTance to Imatinib in GIST |
https://ClinicalTrials.gov/show/NCT03171389 |
Recruiting |
Universität Duisburg-Essen |
2018-09-22 |
| NCT03165721 |
A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer |
https://ClinicalTrials.gov/show/NCT03165721 |
Completed |
National Institutes of Health Clinical Center (CC) |
2020-02-24 |
| NCT03158103 |
A Study of MEK162 (Binimetinib) in Combination With Pexidartinib in Patients With Advanced Gastrointestinal Stromal Tumor (GIST) |
https://ClinicalTrials.gov/show/NCT03158103 |
Active, not recruiting |
Memorial Sloan Kettering Cancer Center |
2021-04-30 |
| NCT03139487 |
A Randomized Phase II Open Label Study to Compare the Safety and Efficacy of Subcutaneous Dalteparin Versus Direct Oral Anticoagulants for Cancer-associated Venous Thromboembolism |
https://ClinicalTrials.gov/show/NCT03139487 |
Recruiting |
Asan Medical Center |
2021-09-30 |
| NCT02931929 |
MITIGATE-NeoBOM: A Study to Evaluate 68Ga- NeoBOMB1 in Patients With Advanced TKI-treated GIST Using PET/CT |
https://ClinicalTrials.gov/show/NCT02931929 |
Completed |
Medical University Innsbruck |
2019-04-09 |
| NCT02924714 |
SSG XXV: The Stop-GIST Trial; Discontinuation of Imatinib in Patients With Oligo-metastatic GIST |
https://ClinicalTrials.gov/show/NCT02924714 |
Recruiting |
Oslo University Hospital |
2022-11-30 |
| NCT02889328 |
Phase II Study of Regorafenib Continuous Dosing of Regorafenib in Patients With GISTs |
https://ClinicalTrials.gov/show/NCT02889328 |
Completed |
Asan Medical Center |
2017-08-09 |
| NCT02884154 |
Feasibility and Yield of a New 20 G ProCore Needle With Coiled Sheath in the Gastrointestinal Subepithelial Tumors |
https://ClinicalTrials.gov/show/NCT02884154 |
Completed |
Pusan National University Hospital |
2017-02-28 |
| NCT02880020 |
Nivolumab With or Without Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumor That Is Metastatic or Cannot Be Removed by Surgery |
https://ClinicalTrials.gov/show/NCT02880020 |
Recruiting |
Jonsson Comprehensive Cancer Center |
2020-09-30 |
| NCT02800330 |
The Effects of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of Regorafenib |
https://ClinicalTrials.gov/show/NCT02800330 |
Completed |
Erasmus Medical Center |
2018-02-28 |
| NCT02686944 |
A Study to Evaluate the Safety of Intuvax Administered Intra-tumorally in Patients With Gastrointestinal Stromal Tumors |
https://ClinicalTrials.gov/show/NCT02686944 |
Completed |
Immunicum AB |
2019-05-10 |
| NCT02638766 |
Single Agent Regorafenib in First-line for Metastatic/Unresectable KIT/PDGFR Wild Type GIST |
https://ClinicalTrials.gov/show/NCT02638766 |
Recruiting |
Grupo Espanol de Investigacion en Sarcomas |
2023-12-31 |
| NCT02607332 |
Paclitaxel in Patients With Metastatic or Advanced Gastrointestinal Stromal Tumors (GIST) After Failure to Imatinib and Sunitinib |
https://ClinicalTrials.gov/show/NCT02607332 |
Completed |
Asan Medical Center |
2018-01-31 |
| NCT02606097 |
Regorafenib in GIST With Secondary C-KIT Exon 17 Mutation |
https://ClinicalTrials.gov/show/NCT02606097 |
Completed |
Chang Gung Memorial Hospital |
2018-05-31 |
| NCT04276415 |
DS-6157a in Participants With Advanced Gastrointestinal Stromal Tumor (GIST) |
https://ClinicalTrials.gov/show/NCT04276415 |
Recruiting |
Daiichi Sankyo, Inc. |
2024-05-31 |
| NCT02574663 |
TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors |
https://ClinicalTrials.gov/show/NCT02574663 |
Completed |
TG Therapeutics, Inc. |
2018-08-31 |
| NCT02571036 |
A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies |
https://ClinicalTrials.gov/show/NCT02571036 |
Recruiting |
Deciphera Pharmaceuticals LLC |
2021-02-28 |
| NCT02508532 |
(NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors |
https://ClinicalTrials.gov/show/NCT02508532 |
Active, not recruiting |
Blueprint Medicines Corporation |
2020-12-31 |
| NCT02500797 |
Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery |
https://ClinicalTrials.gov/show/NCT02500797 |
Active, not recruiting |
National Cancer Institute (NCI) |
2019-04-01 |
| NCT02365441 |
A Randomised Trial of Imatinib Alternating With Regorafenib Compared to Imatinib Alone for the First Line Treatment of Advanced Gastrointestinal Stromal Tumour (GIST) |
https://ClinicalTrials.gov/show/NCT02365441 |
Recruiting |
Australasian Gastro-Intestinal Trials Group |
2019-12-31 |
| NCT02260505 |
Efficiency of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) |
https://ClinicalTrials.gov/show/NCT02260505 |
Recruiting |
Centre Leon Berard |
2022-12-31 |
| NCT02257541 |
BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST) |
https://ClinicalTrials.gov/show/NCT02257541 |
Completed |
Memorial Sloan Kettering Cancer Center |
2019-03-25 |
| NCT02216578 |
Ph II CABOGIST in GIST |
https://ClinicalTrials.gov/show/NCT02216578 |
Active, not recruiting |
European Organisation for Research and Treatment of Cancer - EORTC |
2019-05-20 |
| NCT02164240 |
Phase Ib Study of SUnitinib Alternating With REgorafenib in Patients With Metastatic and/or Unresectable GIST |
https://ClinicalTrials.gov/show/NCT02164240 |
Active, not recruiting |
Dana-Farber Cancer Institute |
2016-12-31 |
| NCT02103322 |
Comparative Bioequivalence Study in Adult Patients Suffering From Chronic Myeloid Leukemia & Gastrointestinal Stromal Tumor Under Fed Conditions |
https://ClinicalTrials.gov/show/NCT02103322 |
Completed |
Amneal Pharmaceuticals, LLC |
2014-03-31 |
| NCT02071862 |
Study of the Glutaminase Inhibitor CB-839 in Solid Tumors |
https://ClinicalTrials.gov/show/NCT02071862 |
Completed |
Calithera Biosciences, Inc |
2019-03-31 |
| NCT01294202 |
A Study to Investigate the Safety and Efficacy of AT13387, Alone or in Combination With Imatinib, in Patients With GIST |
https://ClinicalTrials.gov/show/NCT01294202 |
Completed |
Astex Pharmaceuticals, Inc. |
2013-04-30 |
| NCT01289028 |
Efficacy of Nilotinib in Adult Patients With Gastrointestinal Stromal Tumors Resistant to Imatinib and Sunitinib. |
https://ClinicalTrials.gov/show/NCT01289028 |
Completed |
Novartis |
2014-07-31 |
| NCT01275222 |
Everolimus in Combination With Imatinib in Patients With Glivec Refractory/Resistant Gastrointestinal Stromal Tumors |
https://ClinicalTrials.gov/show/NCT01275222 |
Completed |
Novartis |
2008-09-30 |
| NCT01271712 |
Study of Regorafenib as a 3rd-line or Beyond Treatment for Gastrointestinal Stromal Tumors (GIST) |
https://ClinicalTrials.gov/show/NCT01271712 |
Completed |
Bayer |
2012-01-26 |
| NCT01270984 |
Study to Evaluate the Pharmacokinetic Characteristics of Luckyvec 400mg Tablet, in Healthy Subjects |
https://ClinicalTrials.gov/show/NCT01270984 |
Completed |
Chong Kun Dang Pharmaceutical |
2010-12-31 |
| NCT04282980 |
A Study of DCC-2618 (Ripretinib) Evaluating Efficacy, Safety, and Pharmacokinetics In Patients With Advanced Gastrointestinal Stromal Tumors (GIST) |
https://ClinicalTrials.gov/show/NCT04282980 |
Recruiting |
Zai Lab (Shanghai) Co., Ltd. |
2021-06-30 |
| NCT02015065 |
Phase II Trial of Vandetanib in Children and Adults With Wild-Type Gastrointestinal Stromal Tumors |
https://ClinicalTrials.gov/show/NCT02015065 |
Completed |
National Institutes of Health Clinical Center (CC) |
2016-05-04 |
| NCT01991379 |
MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST) |
https://ClinicalTrials.gov/show/NCT01991379 |
Recruiting |
Memorial Sloan Kettering Cancer Center |
2021-11-30 |
| NCT01907607 |
Efficacy and Safety of PD-0332991 in Patients With Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib |
https://ClinicalTrials.gov/show/NCT01907607 |
Completed |
Institut Bergonié |
2016-12-31 |
| NCT01874665 |
A Phase 2 Trial of Ponatinib in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor |
https://ClinicalTrials.gov/show/NCT01874665 |
Completed |
Takeda |
2015-02-28 |
| NCT01863745 |
Nilotinib Roll-over Protocol for Patients in Novartis-sponsored Nilotinib Study and Benefiting From Nilotinib Treatment |
https://ClinicalTrials.gov/show/NCT01863745 |
Active, not recruiting |
Novartis |
2023-10-04 |
| NCT01774162 |
EUS-guided Fine Needle Biopsy With a New Core Histology Needle Versus Conventional Fine Needle Aspiration |
https://ClinicalTrials.gov/show/NCT01774162 |
Completed |
University of Alberta |
2012-06-30 |
| NCT01769248 |
Prospective Trial of EUS-FNA Versus EUS-FNB Using a Novel Core Biopsy Needle |
https://ClinicalTrials.gov/show/NCT01769248 |
Completed |
Northwestern University |
2014-02-28 |
| NCT01751919 |
A Clinical Trial to Compare the Pharmacokinetics of Imatinib Mesylate Tablet 400mg (1 Tablet) and Glivec Film-coated Tablet 100mg (4 Tablets)(Phase I) |
https://ClinicalTrials.gov/show/NCT01751919 |
Completed |
Dong-A ST Co., Ltd. |
2012-08-31 |
| NCT01738139 |
Ipilimumab and Imatinib Mesylate in Advanced Cancer |
https://ClinicalTrials.gov/show/NCT01738139 |
Recruiting |
M.D. Anderson Cancer Center |
2022-02-28 |
| NCT01735968 |
A Dose-finding Study of a Combination of Imatinib and BYL719 in the Treatment of 3rd Line GIST Patients |
https://ClinicalTrials.gov/show/NCT01735968 |
Completed |
Novartis |
2018-10-19 |
| NCT01694277 |
Masitinib in Patients With Gastrointestinal Stromal Tumour After Progression With Imatinib |
https://ClinicalTrials.gov/show/NCT01694277 |
Active, not recruiting |
AB Science |
2020-06-30 |
| NCT01643278 |
Dasatinib and Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumors or Other Sarcomas That Cannot Be Removed by Surgery or Are Metastatic |
https://ClinicalTrials.gov/show/NCT01643278 |
Completed |
National Cancer Institute (NCI) |
2016-06-30 |
| NCT01541709 |
Imatinib Dose Escalation to 800 mg/Day in Korean Patients With Metastatic or Unresectable GIST Harboring KIT Exon 9 Mutation: KENEDI |
https://ClinicalTrials.gov/show/NCT01541709 |
Active, not recruiting |
Asan Medical Center |
2020-12-31 |
| NCT01506336 |
Masitinib in Patients With Gastro-Intestinal Stromal Tumour Resistant to Imatinib |
https://ClinicalTrials.gov/show/NCT01506336 |
Completed |
AB Science |
2011-09-30 |
| NCT01483014 |
Phase ll Study of Imatinib Mesylate for the Neoadjuvant Treatment of Patients With Gastrointestinal Stromal Tumors (GIST) |
https://ClinicalTrials.gov/show/NCT01483014 |
Completed |
Novartis |
2012-01-31 |
| NCT01478373 |
Efficacy and Safety of Dovitinib in Patients With Gastrointestinal Stromal Tumors Refractory and/or Intolerant to Imatinib |
https://ClinicalTrials.gov/show/NCT01478373 |
Completed |
Novartis |
2014-07-31 |
| NCT01468688 |
A Dose-finding Study of a Combination of Imatinib and BKM120 in the Treatment of 3rd Line GIST Patients |
https://ClinicalTrials.gov/show/NCT01468688 |
Completed |
Novartis |
2016-07-29 |
| NCT01462994 |
Detection of CF-DNA in Patients With Gastrointestinal Stromal Tumors (GIST) |
https://ClinicalTrials.gov/show/NCT01462994 |
Completed |
Technische Universität München |
2015-12-31 |
| NCT01440959 |
Dovitinib for Imatinib/Sumitinib-failed Gastrointestinal Stromal Tumors (GIST): TKI258 |
https://ClinicalTrials.gov/show/NCT01440959 |
Completed |
Asan Medical Center |
2013-03-31 |
| NCT01421680 |
The Effects of Preoperative and Postoperative Oral Nutritional Supplements in Malnourished Post-gastrectomy Patients |
https://ClinicalTrials.gov/show/NCT01421680 |
Completed |
Seoul National University Hospital |
2013-12-31 |
| NCT01404650 |
Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients With Refractory Gastrointestinal Stromal Tumor |
https://ClinicalTrials.gov/show/NCT01404650 |
Completed |
SCRI Development Innovations, LLC |
2015-02-28 |
| NCT01402089 |
Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients |
https://ClinicalTrials.gov/show/NCT01402089 |
Completed |
Cantonal Hospital of St. Gallen |
2015-07-31 |
| NCT01396148 |
A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor |
https://ClinicalTrials.gov/show/NCT01396148 |
Completed |
Pfizer |
2017-08-31 |
| NCT01323400 |
Efficacy of Pazopanib in Gastrointestinal Stromal Tumors (GIST) |
https://ClinicalTrials.gov/show/NCT01323400 |
Completed |
Centre Leon Berard |
2014-04-30 |
| NCT04344847 |
Incidental Finding of Gastrointestinal Stromal Tumors (GISTs) During Laparoscopic Sleeve Gastrectomy, How to Deal? How Much Safety Margin |
https://ClinicalTrials.gov/show/NCT04344847 |
Recruiting |
Zagazig University |
2020-05-13 |
| NCT04258956 |
A Study of Avelumab In Combination With Axitinib in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumor After Failure of Standard Therapy |
https://ClinicalTrials.gov/show/NCT04258956 |
Recruiting |
Maria Sklodowska-Curie Institute - Oncology Center |
2021-04-30 |
| NCT04254939 |
A Study of CS3007 in Subjects With Gastrointestinal Stromal Tumor |
https://ClinicalTrials.gov/show/NCT04254939 |
Recruiting |
CStone Pharmaceuticals |
2020-12-30 |
| NCT04193553 |
Multicentre Placebo-controlled Double-blinded Phase II Study of Lenvatinib Efficacy in Patients With Locally Advanced or Metastatic GIST (Gastrointestinal Stromal Tumor) After Imatinib/Sunitinib Failure |
https://ClinicalTrials.gov/show/NCT04193553 |
Recruiting |
Centre Leon Berard |
2022-03-31 |
| NCT04138381 |
Selinexor in Combination With Imatinib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors. |
https://ClinicalTrials.gov/show/NCT04138381 |
Recruiting |
Grupo Espanol de Investigacion en Sarcomas |
2022-04-16 |
| NCT04106024 |
Efficacy and Safety of Anlotinib in Patients With Advanced Gastrointestinal Stromal Tumor After Failure of Imatinib: a Prospective, Single Arm and Multicenter Trial |
https://ClinicalTrials.gov/show/NCT04106024 |
Recruiting |
Cttq |
2019-10-30 |
| NCT04000529 |
Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies |
https://ClinicalTrials.gov/show/NCT04000529 |
Recruiting |
Novartis |
2022-03-22 |
| NCT03673501 |
A Study of DCC-2618 vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib |
https://ClinicalTrials.gov/show/NCT03673501 |
Recruiting |
Deciphera Pharmaceuticals LLC |
2021-06-30 |
| NCT03609424 |
PDR001 Plus Imatinib for Metastatic or Unresectable GIST |
https://ClinicalTrials.gov/show/NCT03609424 |
Recruiting |
Asan Medical Center |
2020-08-30 |
| NCT03594422 |
A Study of HQP1351 in Patients With GIST or Other Solid Tumors |
https://ClinicalTrials.gov/show/NCT03594422 |
Recruiting |
Ascentage Pharma Group Inc. |
2020-10-30 |
| NCT03556384 |
Temozolomide (TMZ) In Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor (GIST) |
https://ClinicalTrials.gov/show/NCT03556384 |
Recruiting |
University of California, San Diego |
2021-09-30 |
| NCT03471273 |
Comparison of Endoscopic and Laparoscopic Resection for Small Gastric Gastrointestinal Stromal Tumor |
https://ClinicalTrials.gov/show/NCT03471273 |
Recruiting |
Nanfang Hospital of Southern Medical University |
2021-10-30 |
| NCT03465722 |
(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST |
https://ClinicalTrials.gov/show/NCT03465722 |
Active, not recruiting |
Blueprint Medicines Corporation |
2021-04-30 |
| NCT03440515 |
Management of Imatinib-associated Severe Skin Rash in Patients With Gastrointestinal Stromal Tumor |
https://ClinicalTrials.gov/show/NCT03440515 |
Completed |
Asan Medical Center |
2017-06-30 |
| NCT03426722 |
L-carnitine vs Placebo for the Treatment of Muscle Cramps After Imatinib in Gastrointestinal Stromal Tumors |
https://ClinicalTrials.gov/show/NCT03426722 |
Recruiting |
Asan Medical Center |
2020-03-31 |
| NCT01267695 |
Perioperative Imatinib Mesylate in Treating Patients With Locally Advanced Gastrointestinal Stromal Tumor |
https://ClinicalTrials.gov/show/NCT01267695 |
Completed |
Peking University |
2014-10-31 |
| NCT01265810 |
Caphosol in Oral Mucositis Due to Targeted Therapy |
https://ClinicalTrials.gov/show/NCT01265810 |
Completed |
Impaqtt Foundation |
2015-08-31 |
| NCT01243346 |
Study of Crenolanib for the Treatment of Patients With Advanced GIST With the D842-related Mutations and Deletions in the PDGFRA Gene |
https://ClinicalTrials.gov/show/NCT01243346 |
Completed |
Arog Pharmaceuticals, Inc. |
2014-07-31 |
| NCT01154452 |
Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma |
https://ClinicalTrials.gov/show/NCT01154452 |
Completed |
National Cancer Institute (NCI) |
2015-02-28 |
| NCT01151852 |
Rechallenge of Imatinib in GIST Having no Effective Treatment: RIGHT |
https://ClinicalTrials.gov/show/NCT01151852 |
Completed |
Asan Medical Center |
2013-03-31 |
| NCT01114087 |
Impact of the Inhibitors of Tyrosine Kinase on the Male Fertility |
https://ClinicalTrials.gov/show/NCT01114087 |
Completed |
Assistance Publique - Hôpitaux de Paris |
2009-05-31 |
| NCT01091207 |
Sorafenib for Imatinib/Sunitinib-failed GIST |
https://ClinicalTrials.gov/show/NCT01091207 |
Completed |
Samsung Medical Center |
2010-12-31 |
| NCT01068769 |
Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor |
https://ClinicalTrials.gov/show/NCT01068769 |
Active, not recruiting |
Dana-Farber Cancer Institute |
2012-06-30 |
| NCT00998751 |
Masitinib in Locally Advanced/Metastatic Gastro-intestinal Stromal Tumour (GIST) |
https://ClinicalTrials.gov/show/NCT00998751 |
Completed |
AB Science |
2013-06-30 |
| NCT00940563 |
A Prospective, Multicenter Study on Best Clinical Use of Imatinib in the Advanced Gastrointestinal Stromal Tumors |
https://ClinicalTrials.gov/show/NCT00940563 |
Completed |
Novartis |
2004-08-31 |
| NCT00867113 |
Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST) |
https://ClinicalTrials.gov/show/NCT00867113 |
Completed |
Novartis |
2016-12-20 |
| NCT03944304 |
Paclitaxel in Patients With GIST With Low P-glycoprotein Expression After Failure of at Least Imatinib and Sunitinib, and Regorafenib. |
https://ClinicalTrials.gov/show/NCT03944304 |
Recruiting |
Asan Medical Center |
2020-08-01 |
| NCT02401815 |
PLX9486 as a Single Agent and in Combination With PLX3397 or PLX9486 With Sunitinib in Patients With Advanced Solid Tumors |
https://ClinicalTrials.gov/show/NCT02401815 |
Active, not recruiting |
Plexxikon |
2020-05-31 |
| NCT01110668 |
Evaluation of Nilotinib In Patients With Advanced Gastrointestinal Stromal Tumor (GIST) |
https://ClinicalTrials.gov/show/NCT01110668 |
Completed |
Novartis |
2011-09-30 |
| NCT01560260 |
Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors |
https://ClinicalTrials.gov/show/NCT01560260 |
Completed |
National Cancer Institute (NCI) |
2015-10-31 |
| NCT02834013 |
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors |
https://ClinicalTrials.gov/show/NCT02834013 |
Recruiting |
National Cancer Institute (NCI) |
2021-08-31 |
| NCT01172548 |
Safety and Efficacy Evaluation of Two Year Imatinib Treatment in Adjuvant Gastrointestinal Stromal Tumor (GIST) |
https://ClinicalTrials.gov/show/NCT01172548 |
Completed |
Novartis |
2014-03-31 |
| NCT00793871 |
Safety And Efficacy Study Of Sunitinib Malate In Chinese Patients With Imatinib Resistant Or Intolerant Malignant Gastrointestinal Stromal Tumor |
https://ClinicalTrials.gov/show/NCT00793871 |
Completed |
Pfizer |
2014-04-30 |
| NCT00785785 |
A Study of Nilotinib Versus Imatinib in GIST Patients |
https://ClinicalTrials.gov/show/NCT00785785 |
Completed |
Novartis |
2014-10-31 |
| NCT00780494 |
Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma |
https://ClinicalTrials.gov/show/NCT00780494 |
Completed |
Stanford University |
2017-12-31 |
| NCT00769782 |
Surgery in Treating Patients With Liver Metastasis From a Gastrointestinal Stromal Tumor |
https://ClinicalTrials.gov/show/NCT00769782 |
Completed |
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan |
2016-03-31 |
| NCT00764595 |
Imatinib Mesylate in Treating Patients With Liver Metastasis From a Gastrointestinal Stromal Tumor |
https://ClinicalTrials.gov/show/NCT00764595 |
Completed |
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan |
2016-03-31 |
| NCT00756509 |
Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With Nilotinib |
https://ClinicalTrials.gov/show/NCT00756509 |
Active, not recruiting |
Novartis |
2022-12-31 |
| NCT00718562 |
Efficacy and Safety of AMN107 in Patients With GastroIntestinal Stromal Tumors (GIST) Who Have Failed Both Imatinib and Sunitinib |
https://ClinicalTrials.gov/show/NCT00718562 |
Completed |
Novartis |
2013-07-31 |
| NCT00654160 |
Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Gastrointestinal Cancer |
https://ClinicalTrials.gov/show/NCT00654160 |
Completed |
Mayo Clinic |
2010-11-30 |
| NCT00633295 |
Phase II Study Aiming to Evaluate the Efficacy and Safety of Nilotinib Patients With Gastrointestinal Stromal Tumors (GIST) Resistant or Intolerant to Imatinib and or to 2nd Line Tyrosine Kinas (TK) Inhibitor |
https://ClinicalTrials.gov/show/NCT00633295 |
Completed |
Novartis |
2010-05-31 |
| NCT00623831 |
A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen |
https://ClinicalTrials.gov/show/NCT00623831 |
Completed |
Ludwig Institute for Cancer Research |
2012-05-31 |
| NCT00618319 |
An Open-Label, 18FDG-PET Pharmacodynamic Assessment of the Effect of BIIB021 in Subjects With Gastrointestinal Stromal Tumors (GIST) |
https://ClinicalTrials.gov/show/NCT00618319 |
Completed |
Biogen |
2010-04-30 |
| NCT00580281 |
Effect of Imatinib on Bone Metabolism in Patients With Chronic Myelogenous Leukemia or Gastrointestinal Stromal Tumors |
https://ClinicalTrials.gov/show/NCT00580281 |
Completed |
Memorial Sloan Kettering Cancer Center |
2013-10-31 |
| NCT00570635 |
A Phase 2 Study of XL820 in Adults With Advanced GIST Resistant to Imatinib and/or Sunitinib |
https://ClinicalTrials.gov/show/NCT00570635 |
Completed |
Exelixis |
2009-05-31 |
| NCT00568750 |
Dasatinib as First-Line Therapy in Treating Patients With Gastrointestinal Stromal Tumors |
https://ClinicalTrials.gov/show/NCT00568750 |
Completed |
Swiss Group for Clinical Cancer Research |
2012-01-18 |
| NCT00510354 |
Treatment of Patients With Everolimus and Imatinib Mesylate Who Have Progressive Gastro Intestinal Stromal Tumors (GIST) and Are Resistant to Imatinib Mesylate |
https://ClinicalTrials.gov/show/NCT00510354 |
Completed |
Novartis |
2012-11-30 |
| NCT00500188 |
Preoperative and Postoperative Imatinib Mesylate Study in Patients With c-Kit Positive GIST |
https://ClinicalTrials.gov/show/NCT00500188 |
Completed |
M.D. Anderson Cancer Center |
2011-07-31 |
| NCT00471328 |
Efficacy and Safety of Nilotinib (AMN107) Compared With Current Treatment Options in Patients With GIST Who Have Failed Both Imatinib and Sunitinib |
https://ClinicalTrials.gov/show/NCT00471328 |
Completed |
Novartis |
2008-08-31 |
| NCT00464620 |
Trial of Dasatinib in Advanced Sarcomas |
https://ClinicalTrials.gov/show/NCT00464620 |
Completed |
Sarcoma Alliance for Research through Collaboration |
2016-12-31 |
| NCT00457743 |
A Phase I/II Study of Sunitinib Malate (SU011248) In Patients With Gastrointestinal Stromal Tumor (GIST) |
https://ClinicalTrials.gov/show/NCT00457743 |
Completed |
Pfizer |
2008-08-31 |
| NCT00455559 |
Ph II Study of Perifosine Plus Gleevec for Patients With GIST |
https://ClinicalTrials.gov/show/NCT00455559 |
Completed |
AEterna Zentaris |
2010-11-30 |
| NCT00441155 |
Patients Completing Core Protocol (CAMN107A2103), Exhibiting Stable Disease (SD), Partial Response (PR) or Complete Response (CR) to Nilotinib in Combination With Imatinib |
https://ClinicalTrials.gov/show/NCT00441155 |
Completed |
Novartis |
2011-01-31 |
| NCT00428220 |
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study. |
https://ClinicalTrials.gov/show/NCT00428220 |
Completed |
Pfizer |
2014-08-31 |
| NCT01039519 |
A Study Evaluating STA-9090 in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor (GIST) |
https://ClinicalTrials.gov/show/NCT01039519 |
Completed |
Synta Pharmaceuticals Corp. |
2011-12-31 |
| NCT00385203 |
The Biological Activity of Cediranib (AZD2171) in Gastro-Intestinal Stromal Tumours(GIST). |
https://ClinicalTrials.gov/show/NCT00385203 |
Completed |
AstraZeneca |
2008-06-30 |
| NCT00367861 |
Prospective Multicentric Randomized Study of Glivec® in Advanced GIST Expressing C-kit: Interruption After 5 Years vs Maintenance |
https://ClinicalTrials.gov/show/NCT00367861 |
Completed |
Centre Leon Berard |
2012-04-30 |
| NCT00359333 |
Phase II Trial of Locally Advanced/Metastatic Soft Tissue Sarcoma or Advanced/Metastatic Malignant GIST |
https://ClinicalTrials.gov/show/NCT00359333 |
Completed |
National Health Research Institutes, Taiwan |
2010-04-30 |
| NCT00293124 |
Open-label Trial of GlivecWith Unresectable or Metastatic Malignant Gastrointestinal Stromal Tumors |
https://ClinicalTrials.gov/show/NCT00293124 |
Completed |
Central European Cooperative Oncology Group |
2006-07-31 |
| NCT00278876 |
Adjuvant Imatinib in High-risk Gastrointestinal Stromal Tumor (GIST) With C-kit Mutation |
https://ClinicalTrials.gov/show/NCT00278876 |
Completed |
Asan Medical Center |
2007-08-31 |
| NCT00276302 |
Safety Study of IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) or Soft Tissue Sarcomas (STS) |
https://ClinicalTrials.gov/show/NCT00276302 |
Completed |
Infinity Pharmaceuticals, Inc. |
2010-11-30 |
| NCT00265798 |
Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate and Sunitinib Malate |
https://ClinicalTrials.gov/show/NCT00265798 |
Active, not recruiting |
National Cancer Institute (NCI) |
2010-02-11 |
| NCT00254267 |
Evaluate the Efficacy of AMG 706 to Treat Advanced Gastrointestinal Stromal Tumors |
https://ClinicalTrials.gov/show/NCT00254267 |
Completed |
Amgen |
2007-02-28 |
| NCT00237185 |
A Study of the Efficacy and Safety of Imatinib Mesylate in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing C-kit Gene |
https://ClinicalTrials.gov/show/NCT00237185 |
Completed |
Novartis |
2013-06-30 |
| NCT00237172 |
Phase II Clinical Study of Imatinib Mesylate in Patients With Malignant Gastrointestinal Stromal Tumors (Extension Study) |
https://ClinicalTrials.gov/show/NCT00237172 |
Completed |
Novartis |
2005-07-31 |
| NCT00171977 |
Post-Marketing Clinical Study of Postoperative Adjuvant Therapy With Imatinib Mesylate in Patients With Gastrointestinal Stromal Tumors (GIST) |
https://ClinicalTrials.gov/show/NCT00171977 |
Completed |
Novartis |
2009-04-30 |
| NCT00137449 |
Study Of SU011248 Administered On A Continuous Daily Dosing Schedule In Patients With Gastrointestinal Stromal Tumor |
https://ClinicalTrials.gov/show/NCT00137449 |
Completed |
Pfizer |
2008-04-30 |
| NCT00135005 |
Study of AMN107 With Imatinib in Gastrointestinal Stromal Tumors (GIST) |
https://ClinicalTrials.gov/show/NCT00135005 |
Completed |
Novartis |
2006-11-30 |
| NCT00117299 |
PTK787/ZK222584 in the Treatment of Metastatic Gastrointestinal Stromal Tumors Resistant to Imatinib |
https://ClinicalTrials.gov/show/NCT00117299 |
Completed |
University of Helsinki |
2007-09-30 |
| NCT00116935 |
Study Comparing 12 Months Versus 36 Months of Imatinib in the Treatment of Gastrointestinal Stromal Tumor (GIST) |
https://ClinicalTrials.gov/show/NCT00116935 |
Completed |
Scandinavian Sarcoma Group |
2010-12-31 |
| NCT00112632 |
Imatinib Mesylate in Treating Patients With Locally Advanced Gastrointestinal Stromal Tumor |
https://ClinicalTrials.gov/show/NCT00112632 |
Completed |
Technische Universität München |
NA |
| NCT00112463 |
Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma |
https://ClinicalTrials.gov/show/NCT00112463 |
Completed |
National Cancer Institute (NCI) |
2008-10-23 |
| NCT00103168 |
Imatinib Mesylate or Observation Only in Treating Patients Who Have Undergone Surgery for Localized Gastrointestinal Stromal Tumor |
https://ClinicalTrials.gov/show/NCT00103168 |
Completed |
European Organisation for Research and Treatment of Cancer - EORTC |
2008-10-31 |
| NCT00098579 |
Doxorubicin Hydrochloride and Alvocidib in Treating Patients With Metastatic or Recurrent Sarcoma That Cannot Be Removed By Surgery |
https://ClinicalTrials.gov/show/NCT00098579 |
Completed |
National Cancer Institute (NCI) |
2011-07-31 |
| NCT00089960 |
Study of AMG 706 in Subjects With Advanced Gastrointestinal Stromal Tumors (GISTs) |
https://ClinicalTrials.gov/show/NCT00089960 |
Completed |
Amgen |
2006-06-30 |
| NCT00087074 |
CCI-779 in Treating Patients With Soft Tissue Sarcoma or Gastrointestinal Stromal Tumor |
https://ClinicalTrials.gov/show/NCT00087074 |
Completed |
National Cancer Institute (NCI) |
2005-12-31 |
| NCT00003939 |
Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma |
https://ClinicalTrials.gov/show/NCT00003939 |
Completed |
European Organisation for Research and Treatment of Cancer - EORTC |
2000-11-30 |
| NCT00005874 |
Nitrocamptothecin in Treating Patients With Soft Tissue Sarcomas |
https://ClinicalTrials.gov/show/NCT00005874 |
Completed |
National Cancer Institute (NCI) |
NA |
| NCT00005862 |
SU5416 in Treating Patients With Advanced, Metastatic, or Recurrent Soft Tissue Sarcomas |
https://ClinicalTrials.gov/show/NCT00005862 |
Completed |
National Cancer Institute (NCI) |
2004-07-31 |
| NCT00075218 |
A Study To Assess The Safety And Efficacy Of SU11248 In Patients With Gastrointestinal Stromal Tumor(GIST) |
https://ClinicalTrials.gov/show/NCT00075218 |
Completed |
Pfizer |
2008-05-31 |
| NCT00069940 |
Vaccine Therapy and Sargramostim in Treating Patients With Sarcoma or Brain Tumor |
https://ClinicalTrials.gov/show/NCT00069940 |
Completed |
Dana-Farber Cancer Institute |
2006-08-31 |
| NCT00004911 |
Endoscopic Placement of Metal Stent in Patients With Cancer-Related Bowel Obstruction |
https://ClinicalTrials.gov/show/NCT00004911 |
Completed |
Northwestern University |
2003-02-28 |
| NCT00004910 |
Endoscopic Placement of Metal Stents in Treating Patients With Cancer- Related Duodenal Obstruction |
https://ClinicalTrials.gov/show/NCT00004910 |
Completed |
Northwestern University |
2003-02-28 |
| NCT00004895 |
Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery |
https://ClinicalTrials.gov/show/NCT00004895 |
Completed |
Northwestern University |
2002-10-31 |
| NCT00030667 |
Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood |
https://ClinicalTrials.gov/show/NCT00030667 |
Completed |
National Cancer Institute (NCI) |
2005-12-31 |
| NCT00041249 |
Brostallicin in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma |
https://ClinicalTrials.gov/show/NCT00041249 |
Completed |
European Organisation for Research and Treatment of Cancer - EORTC |
2004-01-31 |
| NCT00041197 |
Imatinib Mesylate in Treating Patients With Primary Gastrointestinal Stromal Tumor That Has Been Completely Removed By Surgery |
https://ClinicalTrials.gov/show/NCT00041197 |
Completed |
National Cancer Institute (NCI) |
2007-04-30 |
| NCT00031681 |
7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) |
https://ClinicalTrials.gov/show/NCT00031681 |
Completed |
National Cancer Institute (NCI) |
2011-01-31 |
| NCT00028002 |
Neoadjuvant and Adjuvant Imatinib Mesylate in Treating Patients With Primary or Recurrent Malignant Gastrointestinal Stromal Tumor |
https://ClinicalTrials.gov/show/NCT00028002 |
Completed |
National Cancer Institute (NCI) |
2009-01-28 |
| NCT00025415 |
Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction |
https://ClinicalTrials.gov/show/NCT00025415 |
Completed |
National Cancer Institute (NCI) |
2005-01-31 |
| NCT00025246 |
Imatinib Mesylate in Treating Patients With Gastrointestinal Stromal Tumor That Has Been Completely Removed During Surgery |
https://ClinicalTrials.gov/show/NCT00025246 |
Completed |
National Cancer Institute (NCI) |
2007-11-30 |
| NCT00005597 |
S9926 Temozolomide in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumors |
https://ClinicalTrials.gov/show/NCT00005597 |
Completed |
Southwest Oncology Group |
2005-10-31 |
| NCT00005049 |
Combination Chemotherapy in Treating Patients With Stage III Ovarian Epithelial Cancer or Gastrointestinal Cancer |
https://ClinicalTrials.gov/show/NCT00005049 |
Completed |
NYU Langone Health |
2006-11-30 |
| NCT00006357 |
STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma |
https://ClinicalTrials.gov/show/NCT00006357 |
Completed |
European Organisation for Research and Treatment of Cancer - EORTC |
2001-04-30 |
| NCT00397384 |
Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer |
https://ClinicalTrials.gov/show/NCT00397384 |
Completed |
National Cancer Institute (NCI) |
2013-06-30 |